Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MCARH 109

Next Previous
Drug Profile

MCARH 109

Alternative Names: Anti-GPRC5D CAR T cell therapy - Eureka Therapeutics/Juno Therapeutics/Memorial Sloan Kettering Cancer Center; ET 150; G Protein-coupled Receptor Class C Group 5 Memberane Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells; GPRC5D Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells; MCARH109; MCARH109 T cells

Latest Information Update: 28 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA (Parenteral, Infusion)
  • 28 Sep 2022 Safety and efficacy data from a phase I trial in Multiple myeloma released by Eureka Therapeutics
  • 28 Sep 2022 Eureka Therapeutics plans a clinical trial for Multiple myeloma (Monotherapy, Combination therapy)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top